Combination diuretic therapy in severe congestive heart failure

被引:34
作者
Dormans, TPJ
Gerlag, PGG
Russel, FGM
Smits, P
机构
[1] Univ Nijmegen Hosp, Dept Intens Care, NL-6500 HB Nijmegen, Netherlands
[2] St Joseph Hosp, Dept Internal Med, Veldhoven, Netherlands
[3] Univ Nijmegen Hosp, Dept Pharmacol, NL-6500 HB Nijmegen, Netherlands
关键词
D O I
10.2165/00003495-199855020-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Severe congestive heart failure (CHF) is often characterised by fluid retention. A (chronic) state of overhydration has a negative influence on both the quality of life and prognosis of these patients, Therefore, the use of diuretics remains a cornerstone in the treatment of heart failure. However, diuretic resistance, a failure to correct the hydration state adequately with the use of conventional dosages of loop diuretics, is a frequently occurring complication in the treatment of advanced stages of CHF. Several intra- and extrarenal mechanisms may be involved in the development of diuretic resistance. An important pathophysiological mechanism leading to diuretic resistance seen after chronic use of loop diuretics is the functional adaptation of the distal tubule. Studies in animals demonstrate that the sodium reabsorption capacity of this nephron segment increases significantly when the sodium delivery to this segment is augmented, as is the case during administration of loop diuretics. The use of combinations of diuretics acting on different segments of the nephron appears to be an effective option in the treatment of diuretic resistance. Several combinations have been used; however, the combination of a loop diuretic and a thiazide drug acting on the distal tubule appears to be the most effective. However, since the use of this combination may lead to serious adverse effects such as hypokalaemia, metabolic alkalosis and dehydration, careful monitoring of the patient on combination diuretic therapy is necessary.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 60 条
[1]  
BLANTZ RC, 1987, AM J KIDNEY DIS, V10, P2
[2]   ABSORPTION AND DISPOSITION OF FUROSEMIDE IN CONGESTIVE HEART-FAILURE [J].
BRATER, DC ;
SEIWELL, R ;
ANDERSON, S ;
BURDETTE, A ;
DEHMER, GJ ;
CHENNAVASIN, P .
KIDNEY INTERNATIONAL, 1982, 22 (02) :171-176
[3]  
BRATER DC, 1985, J PHARMACOL EXP THER, V233, P70
[4]   FUROSEMIDE IN PATIENTS WITH HEART-FAILURE - SHIFT IN DOSE-RESPONSE CURVES [J].
BRATER, DC ;
CHENNAVASIN, P ;
SEIWELL, R ;
BECK, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (02) :182-186
[5]   RESISTANCE TO LOOP DIURETICS - WHY IT HAPPENS AND WHAT TO DO ABOUT IT [J].
BRATER, DC .
DRUGS, 1985, 30 (05) :427-443
[6]   BUMETANIDE AND FUROSEMIDE IN HEART-FAILURE [J].
BRATER, DC ;
DAY, B ;
BURDETTE, A ;
ANDERSON, S .
KIDNEY INTERNATIONAL, 1984, 26 (02) :183-189
[7]  
CHANNER KS, 1994, BRIT HEART J, V71, P146
[8]   THIAZIDES WITH LOOP DIURETICS FOR SEVERE CONGESTIVE HEART-FAILURE [J].
CHANNER, KS ;
RICHARDSON, M ;
CROOK, R ;
JONES, JV .
LANCET, 1990, 335 (8694) :922-923
[9]  
CHENNAVASIN P, 1980, J PHARMACOL EXP THER, V215, P77
[10]  
CODY RJ, 1994, ARCH INTERN MED, V154, P1905